2024 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

Welcome to the latest of our Eberhard F. Mammen award announcements. As noted in previous editorials ([Table 1]), Thieme, the publisher of Seminars in Thrombosis & Hemostasis (STH), has created the “Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard Mammen ([Fig. 1]), and in recognition of his contribution to this field and to the journal that he both founded and steered for over three decades. These awards began in 2009, under two categories, “Most Popular Article Awards” and “Young Investigator Awards.” Accordingly, 2024 represents 16 years of award presentations ([Table 1]). Current details and conditions of the award can be summarized as:

Table 1 Previous Editorials related to Eberhard F. Mammen award announcements

1. Favaloro EJ. Welcome to a Special Issue of Seminars in Thrombosis and Hemostasis—The Closing Issue for 2008. Semin Thromb Hemost 2008;34:693–696 2. Favaloro EJ. A Tribute to Eberhard F. Mammen, M.D. (1930–2008). Semin Thromb Hemost 2008;34:703–708 3. Favaloro EJ. Welcome to the first issue of Seminars in Thrombosis and Hemostasis for 2009. Semin Thromb Hemost 2009; 35:1–2. 4. Favaloro EJ. Winners of the Inaugural Eberhard F. Mammen Award for Most Popular Article. Semin Thromb Hemost 2009;35:587–590 5. Favaloro EJ. Editorial. 2009 Eberhard F. Mammen Young Investigator Award Winners. Semin Thromb Hemost 2010;36:469–470 6. Favaloro EJ. Winners of the 2010 Eberhard F. Mammen Award for Most Popular Article during 2008–2009. Semin Thromb Hemost 2010;36(7):685–92. 7. Favaloro EJ. 2011 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2011;37(5):431–9. 8. Favaloro EJ. 2012 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2012;38:425–32. 9. Favaloro EJ. 2013 Eberhard F. Mammen award announcements. Semin Thromb Hemost 39:567–74. 10. Favaloro EJ. 2014 Eberhard F. Mammen award announcements: Part I - most popular articles. Semin Thromb Hemost 2014;40(4):407–12. 11. Favaloro EJ. 2014 Eberhard F. Mammen Award Announcements: Part II - Young Investigator Awards. Semin Thromb Hemost 2014;40(7):718–23. 12. Favaloro EJ. 2015 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2015;41(7):673–9. 13. Favaloro EJ. 2015 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2015;41(8):809–15. 14. Favaloro EJ. 2016 Eberhard F. Mammen Award Announcements: Part I - Most Popular Articles. Semin Thromb Hemost 2016;42(4):325–30. 15. Favaloro EJ. 2016 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2017;43(3):235–241. 16. Favaloro EJ. 2017 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2017;43(4):357–363. 17. Favaloro EJ. 2017 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2018;44(2):81–88. 18. Favaloro EJ. 2018 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2018;44(3):185–192. 19. Favaloro EJ. 2018 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2019;45(2):123–129. 20. Favaloro EJ. 2019 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2019;45(3):215–224. 21. Favaloro EJ. 2019 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards. Semin Thromb Hemost 2020;46(2):105–113 22. Favaloro EJ. 2020 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2020;46(4):383–392. 23. Favaloro EJ. 2020 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2021;47(3):229–237. 24. Favaloro EJ. 2021 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2021;47(5):467–476. 25. Favaloro EJ. 2021 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2022 Apr;48(3):265–273. 26. Favaloro EJ. 2022 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2022 Jul;48(5):502–513. 27. Favaloro EJ. 2023 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2023 Jul;49(5):417–426. 28. Favaloro EJ. 2022 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2023 Nov;49(8):775–782.

Fig. 1 Eberhard F. Mammen (1930–2008).

• ➢ Most Popular Article Awards: awarded to the authors of the most popular articles published in STH in the preceding 2 years as captured in the preceding year. The awards are determined by the Editor in Chief on the basis of user statistics from the publisher Thieme e-Journals. Prefaces, Errata, Letters to the Editor, Editorials, Commentaries, and previous award-winning articles are excluded from further consideration of these awards, which currently comprise two categories—one for “Free Access” articles, and another for a “General Category.” There are two major cash prizes of US$1,000 for each category. In addition, winners of the “General Category” awards are granted “Free Access” status for these articles thereafter.

• ➢ Young Investigator Awards: best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen. Up to six cash prizes of US$1,000 in any year. There are some additional considerations and conditions for the award, and awardees are expected to prepare a review or other paper related to the topic of their presentation (or as otherwise agreed) for publication in STH. Previous award winners are excluded from a second award to enable more individuals to be recognized. After nominations are received, the awardees are selected by a vote of the Senior Editors of STH. Any potential conflicts of interest are managed by first identifying these, and then excluding those with potential conflicts from voting. Finally, given the recent COVID-19 (coronavirus disease 2019) pandemic, many international congresses had become virtual or hybrid meetings, and accordingly, virtual meeting presentations can also be considered for the award.

Further details of the awards and the award winners are posted online (https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077), and previous award winner announcements are also available in print (see [Table 1]).

It is therefore with great pleasure that we would like to announce the latest winners of the 2024 Eberhard F. Mammen awards for the most popular articles from STH, as downloaded in 2023 and as published in the period of 2022 to 2023 inclusive.

2024 “Most Popular” Article Awards

As mentioned, the Most Popular awards are given to the authors of the most popular articles published in STH as determined on the basis of user statistics from the publisher of this journal and covering the preceding 2-year publication period, as captured in the preceding year. Thus, the 2024 “Most Popular” awards are granted to the most popular papers, as downloaded in 2023, and as published in the years 2022 and 2023 inclusive. Previous Eberhard F. Mammen award winning articles are listed in [Table 2]. These articles are currently freely available online (https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077), and no longer qualify for future awards, although some will continue to appear in the most popular download statistics provided by the publisher.

Table 2 Previous most popular award-winning papers

Year	Awarded for
2009	Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost 2005;31(4):381–92.
2009	Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. Semin Thromb Hemost 2006;32(8):803–9.
2010	Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost 2008;34(1):39–57.
2010	Prechel M, Walenga JM. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 2008;34(1):86–96.
2010	Fareed J, Hoppensteadt DA, Fareed D, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 2008;34(1):58–73.
2011	Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost 2009;35(5):515–24.
2011	Mariani G, Bernardi F. Factor VII Deficiency. Semin Thromb Hemost 2009;35(4):400–6.
2012	Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox.” Semin Thromb Hemost 2010;36(1):59–70.
2012	Rak J. Microparticles in cancer. Semin Thromb Hemost 2010;36(8):888–906
2013	Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. Semin Thromb Hemost 2011;37(3):280–97.
2013	Tufano A, Guida A, Dario Di Minno MN, Prisco D, Cerbone AM, Minno GD. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. Semin Thromb Hemost 2011 Apr;37(3):267–74.
2014	Salmela B, Joutsi-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. Semin Thromb Hemost 2012;38(1):23–30.
2014	Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. Semin Thromb Hemost 2012;38(1):47–54.
2014	Kenet G, Aronis S, Berkun Y, Bonduel M, Chan A, Goldenberg NA, Holzhauer S, Iorio A, Journeycake J, Junker R, Male C, Manco-Johnson M, Massicotte P, Mesters R, Monagle P, van Ommen H, Rafini L, Simioni P, Young G, Nowak-Göttl U. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. Semin Thromb Hemost 2011;37(7):802–9.
2015	Tapson VF. Thrombolytic therapy for acute pulmonary embolism. Semin Thromb Hemost 2013;39(4):452–458
2015	George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. Semin Thromb Hemost 2013;39(2):153–160
2015[a]	Hylek EM. Anticoagulation therapy for atrial fibrillation. Semin Thromb Hemost 2013;39(2):147–152
2015[a]	Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. Semin Thromb Hemost 2013;39(2):117–126
2016	de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013;39(6):585–95.
2016	Sethi S, Fervenza FC. Pathology of Renal Diseases Associated with Dysfunction of the Alternative Pathway of Complement: C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome (aHUS). Semin Thromb Hemost 2014;40(4):416–21.
2016[a]	Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. Semin Thromb Hemost 2012;38(7):673–82.
2016[a]	Lippi G, Favaloro EJ, Meschi T, Mattiuzzi C, Borghi L, Cervellin G. E-cigarettes and cardiovascular risk: beyond science and mysticism. Semin Thromb Hemost 2014;40(1):60–5.
2017	Boonyawat K, Crowther MA. Venous Thromboembolism Prophylaxis in Critically Ill Patients. Semin Thromb Hemost 2015;41(1):68–74.
2017	Levi M, Poll TV. Coagulation in Patients with Severe Sepsis. Semin Thromb Hemost 2015;41(1):9–15.
2017[a]	Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost 2014;40(2):163–71.
2017[a]	Warkentin TE. Heparin-Induced Thrombocytopenia in Critically Ill Patients. Semin Thromb Hemost 2015;41(1):49–60.
2017[b]	Favaloro EJ, Lippi G. Laboratory Testing in the Era of Direct or Non-Vitamin K Antagonist Oral Anticoagulants: A Practical Guide to Measuring Their Activity and Avoiding Diagnostic Errors. Semin Thromb Hemost 2015;41(2):208–227.
2018	Gremmel T, Frelinger AL 3rd, Michelson AD. Platelet Physiology. Semin Thromb Hemost 2016 Apr;42(3):191–204.
2018	Mallett SV. Clinical Utility of Viscoelastic Tests of Coagulation (TEG/ROTEM) in Patients with Liver Disease and during Liver Transplantation. Semin Thromb Hemost 2015 Jul;41(5):527–37.
2018[a]	Cuker A, Prak ET, Cines DB. Can immune thrombocytopenia be cured with medical therapy? Semin Thromb Hemost 2015 Jun;41(4):395–404.
2018[a]	Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. Semin Thromb Hemost 2014;40(1):106–14.
2019	Klil-Drori AJ, Tagalakis V. Direct Oral Anticoagulants in End-Stage Renal Disease. Semin Thromb Hemost 2018 Jun;44(4):353–363.
2019	Kitchen S, Tiefenbacher S, Gosselin R. Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies. Semin Thromb Hemost 2017 Apr;43(3):331–337.
2019[a]	Kell DB, Pretorius E. To What Extent Are the Terminal Stages of Sepsis, Septic Shock, Systemic Inflammatory Response Syndrome, and Multiple Organ Dysfunction Syndrome Actually Driven by a Prion/Amyloid Form of Fibrin? Semin Thromb Hemost 2018 Apr;44(3):224–238.
2019[a]	Chighizola CB, Raimondo MG, Meroni PL. Management of Thrombotic Antiphospholipid Syndrome. Semin Thromb Hemost 2018 Jul;44(5):419–426.
2020	Kumar KR, Cowley MJ, Davis RL. Next-generation sequencing and emerging technologies. Semin Thromb Hemost 2019;45(7):661–673
2020	Russo V, Attena E, Mazzone C, Esposito F, Parisi V, Bancone C, Rago A, Nigro G, Sangiuolo R, D' Onofrio A. Nonvitamin K antagonist oral anticoagulants use in patients with atrial fibrillation and bioprosthetic heart valves/prior surgical valve repair: a multicenter clinical practice experience. Semin Thromb Hemost 2018;44(4):364–369
2020[a]	Lippi G, Favaloro EJ, Sanchis-Gomar F. Sudden cardiac and noncardiac death in sports: epidemiology, causes, pathogenesis, and prevention. Semin Thromb Hemost 2018;44(8):780–786
2020[a]	Schreiber K, Breen K, Cohen H, Jacobsen S,Middeldorp S, Pavord S, Regan L, Roccatello D, Robinson SE, Sciascia S, Seed PT, Watkins L, Hunt BJ. HYdroxychloroquine to improve pregnancy outcome in women with AnTIphospholipid Antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin Thromb Hemost 2017;43(6):562–571
2021	Iba T, Levi M, Levy JH. Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Semin Thromb Hemost 2020 Feb;46(1):89–95.
2021	Thomas J, Kostousov V, Teruya J. Bleeding and Thrombotic Complications in the Use of Extracorporeal Membrane Oxygenation. Semin Thromb Hemost 2018 Feb;44(1):20–29.
2021[a]	Gosselin RC, Adcock D, Dorgalaleh A, Favaloro EJ, Lippi G, Pego JM, Regan I, Siguret V. International Council for Standardization in Haematology Recommendations for Hemostasis Critical Values, Tests, and Reporting. Semin Thromb Hemost 2020 Jun;46(4):398–409.
2021[a]	Gosselin RC, Marlar RA. Preanalytical Variables in Coagulation Testing: Setting the Stage for Accurate Results. Semin Thromb Hemost 2019 Jul;45(5):433–448.
2022	Abildgaard A, Madsen SA, Hvas AM. Dosage of Anticoagulants in Obesity: Recommendations Based on a Systematic Review. Semin Thromb Hemost 2020 Nov;46(8):932–969
2022	Grottke O, Mallaiah S, Karkouti K, Saner F, Haas T. Fibrinogen Supplementation and Its Indications. Semin Thromb Hemost 2020 Feb;46(1):38–49
2022[a]	Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and Venous Thromboembolism: A Meta-analysis of Literature Studies. Semin Thromb Hemost 2020 Oct;46(7):763–771
2022[a]	Allaoui A, Khawaja AA, Badad O, Naciri M, Lordkipanidzé M, Guessous F, Zaid Y. Platelet Function in Viral Immunity and SARS-CoV-2 Infection. Semin Thromb Hemost 2021 Jun;47(4):419–426
2023	Branstetter JW, Kiskaddon AL, King MA, Coalter C, Grubbs KM, Fly H, Male C, Brandão L, Goldenberg NA. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Pediatric Venous Thromboembolism Treatment and Thromboprophylaxis: A Systematic Review of the Literature. Semin Thromb Hemost 2021 Sep;47(6):643–653
2023	Ichinose A, Osaki T, Souri M. A Review of Coagulation Abnormalities of Autoimmune Acquired Factor V Deficiency with a Focus on Japan. Semin Thromb Hemost 2022 Mar;48(2):206–218
2023[a] [c]	Lippi G, Favaloro EJ. Cerebral Venous Thrombosis Developing after COVID-19 Vaccination: VITT, VATT, TTS, and More. Semin Thromb Hemost 2022 Feb;48(1):8–14.
2023[a]	Engelen MM, Vandenbriele C, Balthazar T, Claeys E, Gunst J, Guler I, Jacquemin M, Janssens S, Lorent N, Liesenborghs L, Peerlinck K, Pieters G, Rex S, Sinonquel P, Van der Linden L, Van Laer C, Vos R, Wauters J, Wilmer A, Verhamme P, Vanassche T. Venous Thromboembolism in Patients Discharged after COVID-19 Hospitalization. Semin Thromb Hemost 2021 Jun;47(4):362–371.
2023[a]	Parisi R, Costanzo S, Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Different Anticoagulant Regimens, Mortality, and Bleeding in Hospitalized Patients with COVID-19: A Systematic Review and an Updated Meta-Analysis. Semin Thromb Hemost 2021 Jun;47(4):372–391.

^a “Free access” category (first created in 2015).

^b This paper qualified as a “Most Popular” award winner based on objective publisher provided download data; however, as this paper was co-written by the journal Editor in Chief, there was an obvious conflict of interest, and the award was officially declined. This paper is listed here merely as a statement of record.

^c This paper also qualified as a “Most Popular” award winner based on objective publisher provided download data; however, as this paper was co-written by the journal Editor in Chief, there was a similar conflict of interest, and the monetary award was officially declined. This paper is again listed here merely as a statement of record.

There is also an increasingly recognized trend to publish articles under an open-access model, and these, as well as other freely available articles, will therefore have an “inequitable advantage” over other “non-open access/non-freely available” articles in terms of potential for downloads or perceived popularity due to their free accessibility. Accordingly, the publisher of STH has established separate categories of the Most Popular Award for “free-access” papers and an alternate “General Category” (non-free access). Consequently, the most popular papers from each category are identified separately. [Tables 3] and [4] respectively list the top 25 downloaded articles from STH in 2023 (from 2022 and 2023 inclusive), as eligible for either the “free access” ([Table 3])[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] or “general category” ([Table 4])[26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] awards.

Table 3 Most popular papers—“free access” category[a]

Rank	Publication
1	Arachchillage DRJ, Pericleous C. Evolution of Antiphospholipid Syndrome. Semin Thromb Hemost 2023 Apr;49(3):295–304
2	Zidan A, Noureldin A, Kumar SA, Elsebaie A, Othman M. COVID-19 Vaccine- Associated Immune Thrombosis and Thrombocytopenia (VITT): Diagnostic Discrepancies and Global Implications. Semin Thromb Hemost 2023 Feb;49(1):9–14.
3	Bowyer AE, Gosselin RC. Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments. Semin Thromb Hemost 2023 Sep;49(6):609–620.
4	Luijten D, de Jong CMM, Ninaber MK, Spruit MA, Huisman MV, Klok FA. Post-Pulmonary Embolism Syndrome and Functional Outcomes after Acute Pulmonary Embolism. Semin Thromb Hemost 2023 Nov;49(8):848–860.
5	Ortega-Paz L, Talasaz AH, Sadeghipour P, Potpara TS, Aronow HD, Jara-Palomares L, Sholzberg M, Angiolillo DJ, Lip GYH, Bikdeli B. COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment. Semin Thromb Hemost 2023 Nov;49(8):816–832.
6	Favaloro EJ, Henry BM, Lippi G. Is Lupus Anticoagulant a Significant Feature of COVID-19? A Critical Appraisal of the Literature. Semin Thromb Hemost 2022 Feb;48(1):55–71.
7	Warkentin TE, Greinacher A. Laboratory Testing for Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: A Narrative Review. Semin Thromb Hemost 2023 Sep;49(6):621–633.
8	Franchini M, Cappello E, Valdiserra G, Bonaso M, Moretti U, Focosi D, Tuccori M. Investigating a Signal of Acquired Hemophilia Associated with COVID-19 Vaccination: A Systematic Case Review. Semin Thromb Hemost 2023 Feb;49(1):15–26.
9	Iba T, Wada H, Levy JH. Platelet Activation and Thrombosis in COVID-19. Semin Thromb Hemost 2023 Feb;49(1):55–61
10	Petersen RS, Fijen LM, Levi M, Cohn DM. Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation. Semin Thromb Hemost 2022 Nov 23. doi: 10.1055/s-0042-1758820.
11	Grobbelaar LM, Kruger A, Venter C, Burger EM, Laubscher GJ, Maponga TG, Kotze MJ, Kwaan HC, Miller JB, Fulkerson D, Huff W, Chang E, Wiarda G, Bunch CM, Walsh MM, Raza S, Zamlut M, Moore HB, Moore EE, Neal MD, Kell DB, Pretorius E. Relative Hypercoagulopathy of the SARS-CoV-2 Beta and Delta Variants when Compared with the Less Severe Omicron Variants Is Related to TEG Parameters, the Extent of Fibrin Amyloid Microclots, and the Severity of Clinical Illness. Semin Thromb Hemost 2022 Oct;48(7):858–868.
12	Selvadurai MV, Favaloro EJ, Chen VM. Mechanisms of Thrombosis in Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia. Semin Thromb Hemost 2023 Jul;49(5):444–452
13	Rizk JG, Gupta A, Lazo JG Jr, Sardar P, Henry BM, Lavie CJ, Effron MB. To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years. Semin Thromb Hemost 2023 Feb;49(1):62–72.
14	Hartmann J, Dias JD, Pivalizza EG, Garcia-Tsao G. Thromboelastography-Guided Therapy Enhances Patient Blood Management in Cirrhotic Patients: A Meta-analysis Based on Randomized Controlled Trials. Semin Thromb Hemost 2023 Mar;49(2):162–172.
15	Lippi G, Favaloro EJ. Cerebral Venous Thrombosis Developing after COVID-19 Vaccination: VITT, VATT, TTS, and More. Semin Thromb Hemost 2022 Feb;48(1):8–14.
16	Lippi G, Favaloro EJ. What We Know (and Do not Know) Regarding the Pathogenesis of Pulmonary Thrombosis in COVID-19. Semin Thromb Hemost 2023 Feb;49(1):27–33.
17	Hartmann J, Curzen N. Modified Thromboelastography for Peri-interventional Assessment of Platelet Function in Cardiology Patients: A Narrative Review. Semin Thromb Hemost 2023 Mar;49(2):192–200.
18	Gosselin RC, Castellone D, Dorgalaleh A, Hickey K, Lippi G, Moffat K, O'Toole R, Rigano J. International Council for Standardization in Haematology Guidance for New Lot Verification of Coagulation Reagents, Calibrators, and Controls. Semin Thromb Hemost 2023 Nov 15. doi: 10.1055/s-0043-1776405
19	Abate V, Casoria A, Rendina D, Muscariello R, Nuzzo V, Vargas M, Servillo G, Venetucci P, Conca P, Tufano A, Galletti F, Di Minno G. Spontaneous Muscle Hematoma in Patients with COVID-19: A Systematic Literature Review with Description of an Additional Case Series. Semin Thromb Hemost 2022 Feb;48(1):100–108.
20	Schellong S, Ageno W, Casella IB, Chee KH, Schulman S, Singer DE, Desch M, Tang W, Voccia I, Zint K, Goldhaber SZ. Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE Study. Semin Thromb Hemost 2022 Jun;48(4):446–458.
21	Buso G, Mazzolai L, Rueda-Camino JA, Fernández-Capitán C, Jiménez D, Bikdeli B, Lobo JL, Fernández-Reyes JL, Ciammaichella M, Monreal M; RIETE Investigators. Pulmonary Embolism in Patients with COVID-19: Comparison between Different Care Settings. Semin Thromb Hemost 2023 Feb;49(1):34–46.
22	Bahraini M, Dorgalaleh A. The Impact of SARS-CoV-2 Infection on Blood Coagulation and Fibrinolytic Pathways: A Review of Prothrombotic Changes Caused by COVID-19. Semin Thromb Hemost 2022 Feb;48(1):19–30.
23	Candeloro M, Schulman S. Arterial Thrombotic Events in Hospitalized COVID-19 Patients: A Short Review and Meta-Analysis. Semin Thromb Hemost 2023 Feb;49(1):47–54.
24	Favaloro EJ, Henry BM, Lippi G. COVID-19 and Antiphospholipid Antibodies: Time for a Reality Check? Semin Thromb Hemost 2022 Feb;48(1):72–92.
25	Ziemba YC, Abdulrehman J, Hollestelle MJ, Meijer P, Plumhoff E, Hsu P, Selby R. Diagnostic Testing for von Willebrand Disease: Trends and Insights from North American Laboratories over the Last Decade. Semin Thromb Hemost 2022 Sep;48(6):700–710.

^a 2022–2023 inclusive, as downloaded in 2023. Ranking is according to download data provided by journal publisher, and excludes nonqualifying material (e.g., Prefaces, Errata, Letters to the Editor, Editorials, Commentaries); however, previous award-winning articles may be listed for recording purposes—these do not, however, qualify for another award.

Table 4 Most popular papers—“general” (non-free access) category[a]

Rank	Publication
1	Iba T, Levi M, Thachil J, Levy JH. Disseminated Intravascular Coagulation: The Past, Present, and Future Considerations. Semin Thromb Hemost 2022 Nov;48(8):978–987.
2	Franchini M, Mannucci PM. The More Recent History of Hemophilia Treatment. Semin Thromb Hemost 2022 Nov;48(8):904–910
3	Hellfritzsch M, Henriksen JN, Holt MI, Grove EL. Drug-Drug Interactions in the Treatment of Cancer-Associated Venous Thromboembolism with Direct Oral Anticoagulants. Semin Thromb Hemost 2024;50(3):489–498.
4	Moore GW. Testing for Lupus Anticoagulants. Semin Thromb Hemost 2022 Sep;48(6):643–660.
5	Morrow GB, Mutch NJ. Past, Present, and Future Perspectives of Plasminogen Activator Inhibitor 1 (PAI-1). Semin Thromb Hemost 2023 Apr;49(3):305–313.
6	Warren BB, Moyer GC, Manco-Johnson MJ. Hemostasis in the Pregnant Woman, the Placenta, the Fetus, and the Newborn Infant. Semin Thromb Hemost 2023 Jun;49(4):319–329.
7	Levy-Mendelovich S, Cohen O, Klang E, Kenet G. 50 Years of Pediatric Hemostasis: Knowledge, Diagnosis, and Treatment. Semin Thromb Hemost 2023 Apr;49(3):217–224.
8	Nogami K. Clot Waveform Analysis for Monitoring Hemostasis. Semin Thromb Hemost 2023 Sep;49(6):592–599
9	Lira AL, Kohs TCL, Moellmer SA, Shatzel JJ, McCarty OJT, Puy C. Substrates, Cofactors, and Cellular Targets of Coagulation Factor XIa. Semin Thromb Hemost 2023 Mar 20. doi: 10.1055/s-0043-1764469.
10	Thachil J. Protamine-The Journey from DNA to Heparin Neutralization to Gene therapy. Semin Thromb Hemost 2022 Mar;48(2):240–243.
11	Pruthi RK, Chen D. The Use of Bypassing Treatment Strategies in Hemophilia and Their Effect on Laboratory Testing. Semin Thromb Hemost 2023 Sep;49(6):651–660
12	George JN. Thrombotic Thrombocytopenic Purpura: From 1972 to 2022 and Beyond. Semin Thromb Hemost 2022 Nov;48(8):926–936.
13	Larsen JB, Hvas AM, Hojbjerg JA. Platelet Function Testing: Update and Future Directions. Semin Thromb Hemost 2023 Sep;49(6):600–608.
14	Kearney KJ, Spronk HMH, Emsley J, Key NS, Philippou H. Plasma Kallikrein as a Forgotten Clotting Factor. Semin Thromb Hemost 2023 Apr 18. doi: 10.1055/s-0043-57034
15	Li W, Hobson EC, Bunch CM, Miller JB, Nehme J, Kwaan HC, Walsh MM, McCurdy MT, Aversa JG, Thomas AV, Zackariya N, Thomas SJ, Smith SA, Cook BC, Boyd B, Stegemann JP, Deng CX. Resonant Acoustic Rheometry to Measure Coagulation Kinetics in Hemophilia A and Healthy Plasma: A Novel Viscoelastic Method. Semin Thromb Hemost 2023 Mar;49(2):201–208.
16	Shamanaev A, Litvak M, Ivanov I, Srivastava P, Sun MF, Dickeson SK, Kumar S, He TZ, Gailani D. Factor XII Structure-Function Relationships. Semin Thromb Hemost 2023 Jun 5:10.1055/s-0043-1769509. doi: 10.1055/s-0043-1769509.
17	Valerio L, Baddour LM. Septic Pulmonary Embolism: A Contemporary Profile. Semin Thromb Hemost 2023 Nov;49(8):840–847.
18	Richard M, Celeny D, Neerman-Arbez M. Mutations Accounting for Congenital Fibrinogen Disorders: An Update. Semin Thromb Hemost 2022 Nov;48(8):889–903.
19	Hirsh J, de Vries TAC, Eikelboom JW, Bhagirath V, Chan NC. Clinical Studies with Anticoagulants that Have Changed Clinical Practice. Semin Thromb Hemost 2023 Apr;49(3):242–254.
20	Casini A, Moerloose P, Neerman-Arbez M. One Hundred Years of Congenital Fibrinogen Disorders. Semin Thromb Hemost 2022 Nov;48(8):880–888.
21	Andersson NG, Kenet G. Intracranial Hemorrhages in Neonates: Incidence, Risk Factors, and Treatment. Semin Thromb Hemost 2023 Jun;49(4):409–415.
22	Ichinose A, Osaki T, Souri M, Favaloro EJ. A Review of Autoimmune Acquired von Willebrand Factor Deficiency in Japan. Semin Thromb Hemost 2022 Nov;48(8):911–925.
23	Malinowski AK, Abdul-Kadir R. Planning Pregnancy and Birth in Women with Inherited Bleeding Disorders. Semin Thromb Hemost 2023 Jun;49(4):371–381.
24	Marlar RA. Laboratory Evaluation of Antithrombin, Protein C, and Protein S. Semin Thromb Hemost 2023 Sep;49(6):641–650.
25	Woods AI, Paiva J, Dos Santos C, Alberto MF, Sánchez-Luceros A. From the Discovery of ADAMTS13 to Current Understanding of Its Role in Health and Disease. Semin Thromb Hemost 2023 Apr;49(3):284–294.

^a 2022–2023 inclusive, as downloaded in 2023. Ranking is according to download data provided by journal publisher, and excludes nonqualifying material (e.g., Prefaces, Errata, Letters to the Editor, Editorials, Commentaries, and previous award-winning articles).

For the prior 2023 awards, the majority of the most popular “free access” papers (13/15 of the top downloaded, including all award-winning papers) were related to COVID-19. As 2023 is no longer considered a pandemic, and as journals transition back to “business as usual,” COVID-19 papers, while remaining popular, do not seem to entirely dominate as in the recent past. Nevertheless, 16/25 papers in the top 25 list have some connection to COVID-19, with 4 of these actually related to vaccine-induced immune thrombotic thrombocytopenia (VITT),[2] [7] [12] [15] a rare but serious condition arising from vaccination against COVID-19.

For the 2024 most popular awards, the top downloaded paper, was unrelated to COVID-19, being a historical account of the evolution of antiphospholipid syndrome, by the authorship team of Arachchillage and Pericleous.[1] The second most popular paper, from Zidan et al, was related to VITT.[2] Thus, the winners of the 2024 most popular awards for the “free access” category are:

• Arachchillage DRJ, Pericleous C. Evolution of Antiphospholipid Syndrome. Semin Thromb Hemost 2023 Apr;49(3):295–304.

• Zidan A, Noureldin A, Kumar SA, Elsebaie A, Othman M. COVID-19 Vaccine- Associated Immune Thrombosis and Thrombocytopenia (VITT): Diagnostic Discrepancies and Global Implications. Semin Thromb Hemost 2023 Feb;49(1):9–14.

Also worth noting from [Table 3] is that two of the papers on the list have not yet as yet been published in an issue, being available only on eFirst within the 2022 to 2023 publication period.[10] [18] This, therefore, should be marked as a special achievement for these papers. Similarly, one of the papers derived from a previous Young Investigator award winner.[12]

General Category

The publisher of STH, Thieme, had in the past provided most material related to COVID-19 as free to download, and so COVID19-related material is less likely to be itemized in the “general category” list of most popular.[26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] The 25 most popular non-free to download papers are listed in [Table 4]. The first two papers listed are the official winners of the 2024 Most Popular in the general category. However, Professor Iba indicated that as he previously won an award (in 2021; see [Table 2]), and since he has recently joined the STH Editorial Board, that he would decline the cash prize, and asked to pay this cash prize forward to enable another awardee. The publisher has agreed to this, and thus the three winners for this category are:

• Iba T, Levi M, Thachil J, Levy JH. Disseminated Intravascular Coagulation: The Past, Present, and Future Considerations. Semin Thromb Hemost 2022 Nov;48(8):978–987.[*]

• Franchini M, Mannucci PM. The More Recent History of Hemophilia Treatment. Semin Thromb Hemost 2022 Nov;48(8):904–910.

• Hellfritzsch M, Henriksen JN, Holt MI, Grove EL. Drug-Drug Interactions in the Treatment of Cancer-Associated Venous Thromboembolism with Direct Oral Anticoagulants. Semin Thromb Hemost 2024;50(3):489–498.

Of interest, the first two are historical accounts into thrombosis and hemostasis, the first into disseminated intravascular coagulation (DIC)[26] and the second into hemophilia treatment.[27] As already noted, Professors Iba, Levi, and Levy, co-authors of the most popular paper, were also winners of the 2021 Most Popular Award for the General Category for a similarly themed paper.[51]

But perhaps most striking is the high number of historically themed papers in the two listings ([Tables 3] and [4]). Not only are 3 of the papers listed as winning the most popular awards[1] [26] [27] historically themed papers, 11 papers in the [Table 3] and [4] listings have a historical focus, and were published in issues aiming to celebrate 50 years of publishing for STH.[52] [53] An additional issue themed around the history of hemostasis and thrombosis was published as the first issue of 2024,[54] and one final issue is planned to be published later this year. We expect to see papers from these issues in the 2025 Most Popular Award announcements!

As always, I always get considerable satisfaction in announcing these awards. This year saw the topic of COVID-19 once again feature, but perhaps take less prominence, with historical content perhaps eclipsing COVID-19 on this occasion. Also, several of the leading COVID-19-related papers in the top listings ([Tables 3] and [4]) were not really on COVID-19, but rather on VITT, representing a rare but serious adverse event in some people immunized against COVID-19, most notably using adenovirus-based vaccines.[55] [56]

In total, considering the top 25 papers in the “Free to download” most popular ([Table 3]) and the top 25 papers in the general category most popular ([Table 4]), the most popular issues were:

• Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)-Part IV. Guest Editors: Favaloro EJ, Pasalic L, Lippi G[57] (7 papers listed in [Tables 3] and [4]).

• Laboratory Diagnostics for Thrombosis and Hemostasis Testing-Part II. Guest Editors: Smock KJ, Gosselin RC[58] (6 papers listed in [Tables 3] and [4]).

• Celebrating 50 Years of Seminars in Thrombosis and Hemostasis-Part I.[52] Guest Editor: Favaloro EJ (6 papers listed in [Tables 3] and [4]).

• Celebrating 50 Years of Seminars in Thrombosis and Hemostasis-Part II.[53] Guest Editor: Favaloro EJ (5 papers listed in [Tables 3] and [4]).

• Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)-Part III. Guest Editors: Favaloro EJ, Lippi G[59] (5 papers listed in [Tables 3] and [4]).

Other Popular Articles

Readers may also be interested to know what other papers were popular in 2023. [Table 5] provides a list of the 30 most popular papers published in STH before 2022. These papers also achieved high download status, but being published before 2022 do not qualify for the 2024 Most Popular Award. Indeed, many of the papers on this list actually represent past Most Popular Award-winning articles, and are now freely available to download. Indeed, all the papers listed in [Table 5] are free to download from the publisher Web site (https://www.thieme-connect.de/products/ejournals/journal/10.1055/s-00000077).

Table 5 Most popular papers in 2023 published before 2022[a]

Rank	Publication
1	Kumar KR, Cowley MJ, Davis RL. Next-Generation Sequencing and Emerging Technologies. Semin Thromb Hemost 2019 Oct;45(7):661–673.
2	Gremmel T, Frelinger AL 3rd, Michelson AD. Platelet Physiology. Semin Thromb Hemost 2016 Apr;42(3):191–204.
3	Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost 2005;31(4):381–92.
4	Abildgaard A, Madsen SA, Hvas AM. Dosage of Anticoagulants in Obesity: Recommendations Based on a Systematic Review. Semin Thromb Hemost 2020 Nov;46(8):932–969.
5	Gosselin RC, Adcock D, Dorgalaleh A, Favaloro EJ, Lippi G, Pego JM, Regan I, Siguret V. International Council for Standardization in Haematology Recommendations for Hemostasis Critical Values, Tests, and Reporting. Semin Thromb Hemost 2020 Jun;46(4):398–409.
6	Gosselin RC, Marlar RA. Preanalytical Variables in Coagulation Testing: Setting the Stage for Accurate Results. Semin Thromb Hemost 2019 Jul;45(5):433–448.
7	Iba T, Levi M, Levy JH. Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Semin Thromb Hemost 2020 Feb;46(1):89–95.
8	Thomas J, Kostousov V, Teruya J. Bleeding and Thrombotic Complications in the Use of Extracorporeal Membrane Oxygenation. Semin Thromb Hemost 2018 Feb;44(1):20–29.
9	Grottke O, Mallaiah S, Karkouti K, Saner F, Haas T. Fibrinogen Supplementation and Its Indications. Semin Thromb Hemost 2020 Feb;46(1):38–49.
10	Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008 Nov;34(8):709–33.
11	Al-Samkari H, Kuter DJ. Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment. Semin Thromb Hemost 2020 Apr;46(3):275–288.
12	Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox.” Semin Thromb Hemost 2010 Feb;36(1):59–70.
13	Rak J. Microparticles in cancer. Semin Thromb Hemost 2010 Nov;36(8):888–906.
14	Laridan E, Martinod K, De Meyer SF. Neutrophil Extracellular Traps in Arterial and Venous Thrombosis. Semin Thromb Hemost 2019 Feb;45(1):86–93.
15	Schreiber K, Breen K, Cohen H, Jacobsen S, Middeldorp S, Pavord S, Regan L, Roccatello D, Robinson SE, Sciascia S, Seed PT, Watkins L, Hunt BJ. HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies. Semin Thromb Hemost 2017 Sep;43(6):562–571.
16	Olson SR, Shatzel JJ, Tao D, Wasp G, DeLoughery TG. Evaluating the Effects of an Evidence-Based Hemostasis and Thrombosis Treatment Algorithm on Medical Practitioner and Trainee Clinical Decision-Making. Semin Thromb Hemost 2018 Jun;44(4):400–403.
17	de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013 Sep;39(6):585–95.
18	Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and Venous Thromboembolism: A Meta-analysis of Literature Studies. Semin Thromb Hemost 2020 Oct;46(7):763–771.
19	Mariani G, Bernardi F. Factor VII Deficiency. Semin Thromb Hemost 2009 Jun;35(4):400–6.
20	Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost 2014 Mar;40(2):163–71.
21	Tufano A, Guida A, Dario Di Minno MN, Prisco D, Cerbone AM, Minno GD. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. Semin Thromb Hemost 2011 Apr;37(3):267–74.
22	Boonyawat K, Crowther MA. Venous Thromboembolism Prophylaxis in Critically Ill Patients. Semin Thromb Hemost 2015 Feb;41(1):68–74.
23	Thachil J, Srivastava A. SARS-2 Coronavirus-Associated Hemostatic Lung Abnormality in COVID-19: Is It Pulmonary Thrombosis or Pulmonary Embolism? Semin Thromb Hemost 2020 Oct;46(7):777–780.
24	Lippi G, Favaloro EJ, Meschi T, Mattiuzzi C, Borghi L, Cervellin G. E-cigarettes and cardiovascular risk: beyond science and mysticism. Semin Thromb Hemost 2014 Feb;40(1):60–5.
25	Engelen MM, Vandenbriele C, Balthazar T, Claeys E, Gunst J, Guler I, Jacquemin M, Janssens S, Lorent N, Liesenborghs L, Peerlinck K, Pieters G, Rex S, Sinonquel P, Van der Linden L, Van Laer C, Vos R, Wauters J, Wilmer A, Verhamme P, Vanassche T. Venous Thromboembolism in Patients Discharged after COVID-19 Hospitalization. Semin Thromb Hemost 2021 Jun;47(4):362–371.
26	Favaloro EJ, Pasalic L, Curnow J. Type 2M and Type 2A von Willebrand Disease: Similar but Different. Semin Thromb Hemost 2016 Jul;42(5):483–97.
27	Favaloro EJ, Henry BM, Lippi G. Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis. Semin Thromb Hemost 2021 Jun;47(4):400–418.
28	Mallett SV. Clinical Utility of Viscoelastic Tests of Coagulation (TEG/ROTEM) in Patients with Liver Disease and during Liver Transplantation. Semin Thromb Hemost 2015 Jul;41(5):527–37.
29	Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost 2009 Mar;35(2):189–203.
30	Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. Semin Thromb Hemost 2012 Oct;38(7):673–82.

^a These papers were also highly downloaded in 2023, but were published before 2022, and so do not qualify for the 2024 Most Popular Awards. Many of these papers were prior Most Popular Awards winning articles (refer to Table 2).

Responses from Award Winners

All authors of the award-winning articles were thrilled to hear that their papers had won an Eberhard F. Mammen Most Popular award, and provided their own personal responses to the news.

From Deepa Arachchillage ([Fig. 2]), on behalf of both authors, “We are truly privileged to receive one of the 2024 Eberhard F. Mammen Seminars in Thrombosis and Hemostasis Most Popular Article Awards in the ‘Free to download' Category’ on our paper ‘Arachchillage DRJ, Pericleous C. Evolution of Antiphospholipid Syndrome. Semin Thromb Hemost 2023 Apr;49(3):295–304’. We are thrilled and pleasantly surprised to hear that our paper is well received and contributing to increasing awareness of antiphospholipid syndrome. Our manuscript outlines the evolution of antiphospholipid syndrome from the initial identification of patients with so-called biological false-positive serological reactions for syphilis in the mid-20th century, to clinical definition of antiphospholipid syndrome in the 1980s and leading to current management strategies for both thrombotic and obstetric complications. We hope our manuscript will continue to serve as a succinct resource outlining this information. I would like to thank my co-author Dr. Pericleous for her contribution and input to improve the relevance of this paper. I am grateful for the invitation to submit this paper to STH and the opportunity to share our knowledge with the readership of STH, and we are truly honored to have had the contribution rewarded by this honor.”

Fig. 2 Deepa Arachchillage.

From Ali Zidan, speaking on behalf of all authors (all of whom appear in [Fig. 3]), “We are honored to receive one of the 2024 Eberhard F. Mammen Seminars in Thrombosis and Hemostasis awards. While there has been a plethora of publications on VITT, our manuscript provided a concise summary of key information regarding the pathology, diagnosis and management of this condition. More importantly, we attempted to highlight the discrepancies reported in the literature and also focused on the global implication of VITT; both remain a concern among the international community. We are grateful to know that this information was widely read by the scientific community who aim to alleviate the burden of COVID-19 and its related complexities. I would like to thank my wonderful co-authors for all their contributions and Dr. Maha Othman for her leadership within our laboratory group. Lastly, a special gratitude to the editors and Dr. Favaloro for the opportunity to present our findings in this respected journal.”

Fig. 3 (Top row; left to right): Ali Zidan, Shreya Anil Kumar. (Bottom row; left to right): Abdelrahman Noureldin, Abdelrahman Elsebaie, Dr. Maha Othman.

From Toshiaki Iba, speaking on behalf of all authors ([Fig. 4], with Jerrold Levy): “It is our great pleasure to have received one of the Eberhard F. Mammen 2024 Most Popular Article Awards in the ‘General’ Category. This marks the second time we have received this honor, the first being in 2021, with both articles focused on DIC. We have been dedicated to studying this significant, yet currently lacking effective treatment, issue for more than 20 years and will continue our research to improve future DIC diagnosis and treatment.”

Fig. 4 Jerrold Levy (left) and Toshiaki Iba (right).

From Massimo Franchini ([Fig. 5]), also on behalf of Pier Mannuccio Mannucci ([Fig. 6]), “We are very excited to hear that our article ‘The more recent history of hemophilia treatment’ received one of the STH 2024 Eberhard F. Mammen Most Popular Article Awards for the ‘General Category’. We are deeply honored for this prestigious award. Our article traces the exciting and amazing history of the treatment of hemophilia, which represents the monogenic disease where the greatest therapeutic progress has been made. We thank the STH readers for their interest in our paper and the Editor in Chief of the journal for his continuous support of our research.”

Fig. 5 Massimo Franchini.

Fig. 6 Pier Mannuccio Mannucci.

From Maja Hellfritzsch ([Fig. 7]), on behalf of the authorship group, “We are very honored to receive one of the Eberhard F. Mammen Seminars in Thrombosis and Hemostasis 2024 Most Popular Article Awards for the ‘General’ Category for our article ‘Drug–drug interactions in the Treatment of Cancer-Associated Venous Thromboembolism with Direct Oral Anticoagulants’. In recent years, increasing evidence supporting the use of direct oral anticoagulants (DOACs) in patients with cancer have emerged. As a result, several guidelines recommend the use of DOACs in this setting. However, concerns of drug–drug interactions between DOACs and antineoplastic therapies have resulted in a hesitance to use DOAC in cancer patients in clinical practice. With an overall aim to ensure optimal anticoagulant therapy to cancer patients, we therefore found it essential to provide specific guidance on this clinically challenging issue. We were truly grateful that our work was chosen for publication in Seminars in Thrombosis & Hemostasis as a part of a special issue on cancer-associated thrombosis, and we are very pleased to now learn that our article has been of great interest to the readers of Seminars in Thrombosis & Hemostasis.”

Fig. 7 Maja Hellfritzsch.

I would, as always, like to thank not only all the authors listed in [Tables 2] to [4], but also all the other contributing authors that did not manage to make these listings, as well as all the many other guest editors of issues recently published in STH. I likewise look forward to seeing future listings—always a great pleasure and sometimes a surprise.

Conflict of Interest

None declared.

^* Professor Iba has declined the cash prize.

• References

• 1 Arachchillage DRJ, Pericleous C. Evolution of antiphospholipid syndrome. Semin Thromb Hemost 2023; 49 (03) 295-304
• 2 Zidan A, Noureldin A, Kumar SA, Elsebaie A, Othman M. COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): diagnostic discrepancies and global implications. Semin Thromb Hemost 2023; 49 (01) 9-14
• 3 Bowyer AE, Gosselin RC. Factor VIII and factor IX activity measurements for hemophilia diagnosis and related treatments. Semin Thromb Hemost 2023; 49 (06) 609-620
• 4 Luijten D, de Jong CMM, Ninaber MK, Spruit MA, Huisman MV, Klok FA. Post-pulmonary embolism syndrome and functional outcomes after acute pulmonary embolism. Semin Thromb Hemost 2023; 49 (08) 848-860
• 5 Ortega-Paz L, Talasaz AH, Sadeghipour P. et al. COVID-19-associated pulmonary embolism: review of the pathophysiology, epidemiology, prevention, diagnosis, and treatment. Semin Thromb Hemost 2023; 49 (08) 816-832
• 6 Favaloro EJ, Henry BM, Lippi G. Is lupus anticoagulant a significant feature of COVID-19? A critical appraisal of the literature. Semin Thromb Hemost 2022; 48 (01) 55-71
• 7 Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia antibodies: a narrative review. Semin Thromb Hemost 2023; 49 (06) 621-633
• 8 Franchini M, Cappello E, Valdiserra G. et al. Investigating a signal of acquired hemophilia associated with COVID-19 vaccination: a systematic case review. Semin Thromb Hemost 2023; 49 (01) 15-26
• 9 Iba T, Wada H, Levy JH. Platelet activation and thrombosis in COVID-19. Semin Thromb Hemost 2023; 49 (01) 55-61
• 10 Petersen RS, Fijen LM, Levi M, Cohn DM. Hereditary angioedema: the clinical picture of excessive contact activation. Semin Thromb Hemost 2022; (e-pub ahead of print) DOI: 10.1055/s-0042-1758820.
• 11 Grobbelaar LM, Kruger A, Venter C. et al. Relative hypercoagulopathy of the SARS-CoV-2 beta and delta variants when compared to the less severe omicron variants is related to TEG parameters, the extent of fibrin amyloid microclots, and the severity of clinical illness. Semin Thromb Hemost 2022; 48 (07) 858-868
• 12 Selvadurai MV, Favaloro EJ, Chen VM. Mechanisms of thrombosis in heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia. Semin Thromb Hemost 2023; 49 (05) 444-452
• 13 Rizk JG, Gupta A, Lazo Jr JG. et al. To anticoagulate or not to anticoagulate in COVID-19: lessons after 2 years. Semin Thromb Hemost 2023; 49 (01) 62-72
• 14 Hartmann J, Dias JD, Pivalizza EG, Garcia-Tsao G. Thromboelastography-guided therapy enhances patient blood management in cirrhotic patients: a meta-analysis based on randomized controlled trials. Semin Thromb Hemost 2023; 49 (02) 162-172
• 15 Lippi G, Favaloro EJ. Cerebral venous thrombosis developing after COVID-19 vaccination: VITT, VATT, TTS, and more. Semin Thromb Hemost 2022; 48 (01) 8-14
• 16 Lippi G, Favaloro EJ. What we know (and do not know) regarding the pathogenesis of pulmonary thrombosis in COVID-19. Semin Thromb Hemost 2023; 49 (01) 27-33
• 17 Hartmann J, Curzen N. Modified thromboelastography for peri-interventional assessment of platelet function in cardiology patients: a narrative review. Semin Thromb Hemost 2023; 49 (02) 192-200
• 18 Gosselin RC, Castellone D, Dorgalaleh A. et al. International Council for Standardization in Haematology guidance for new lot verification of coagulation reagents, calibrators, and controls. Semin Thromb Hemost 2023; (e-pub ahead of print) DOI: 10.1055/s-0043-1776405.
• 19 Abate V, Casoria A, Rendina D. et al. Spontaneous muscle hematoma in patients with COVID-19: a systematic literature review with description of an additional case series. Semin Thromb Hemost 2022; 48 (01) 100-108
• 20 Schellong S, Ageno W, Casella IB. et al. Profile of patients with isolated distal deep vein thrombosis versus proximal deep vein thrombosis or pulmonary embolism: RE-COVERY DVT/PE study. Semin Thromb Hemost 2022; 48 (04) 446-458
• 21 Buso G, Mazzolai L, Rueda-Camino JA. et al; RIETE Investigators. Pulmonary embolism in patients with COVID-19: comparison between different care settings. Semin Thromb Hemost 2023; 49 (01) 34-46
• 22 Bahraini M, Dorgalaleh A. The impact of SARS-CoV-2 infection on blood coagulation and fibrinolytic pathways: a review of prothrombotic changes caused by COVID-19. Semin Thromb Hemost 2022; 48 (01) 19-30
• 23 Candeloro M, Schulman S. Arterial thrombotic events in hospitalized COVID-19 patients: a short review and meta-analysis. Semin Thromb Hemost 2023; 49 (01) 47-54
• 24 Favaloro EJ, Henry BM, Lippi G. COVID-19 and antiphospholipid antibodies: time for a reality check?. Semin Thromb Hemost 2022; 48 (01) 72-92
• 25 Ziemba YC, Abdulrehman J, Hollestelle MJ. et al. Diagnostic testing for von Willebrand disease: trends and insights from North American laboratories over the last decade. Semin Thromb Hemost 2022; 48 (06) 700-710
• 26 Iba T, Levi M, Thachil J, Levy JH. Disseminated intravascular coagulation: the past, present, and future considerations. Semin Thromb Hemost 2022; 48 (08) 978-987
• 27 Franchini M, Mannucci PM. The more recent history of hemophilia treatment. Semin Thromb Hemost 2022; 48 (08) 904-910
• 28 Hellfritzsch M, Henriksen JN, Holt MI, Grove EL. Drug-drug interactions in the treatment of cancer-associated venous thromboembolism with direct oral anticoagulants. Semin Thromb Hemost 2024; 50 (03) 489-498
• 29 Moore GW. Testing for lupus anticoagulants. Semin Thromb Hemost 2022; 48 (06) 643-660
• 30 Morrow GB, Mutch NJ. Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1). Semin Thromb Hemost 2023; 49 (03) 305-313
• 31 Warren BB, Moyer GC, Manco-Johnson MJ. Hemostasis in the pregnant woman, the placenta, the fetus, and the newborn infant. Semin Thromb Hemost 2023; 49 (04) 319-329
• 32 Levy-Mendelovich S, Cohen O, Klang E, Kenet G. 50 years of pediatric hemostasis: knowledge, diagnosis, and treatment. Semin Thromb Hemost 2023; 49 (03) 217-224
• 33 Nogami K. Clot waveform analysis for monitoring hemostasis. Semin Thromb Hemost 2023; 49 (06) 592-599
• 34 Lira AL, Kohs TCL, Moellmer SA, Shatzel JJ, McCarty OJT, Puy C. Substrates, cofactors, and cellular targets of coagulation factor XIa. Semin Thromb Hemost 2023; (e-pub ahead of print) DOI: 10.1055/s-0043-1764469.
• 35 Thachil J. Protamine-the journey from DNA to heparin neutralization to gene therapy. Semin Thromb Hemost 2022; 48 (02) 240-243
• 36 Pruthi RK, Chen D. The use of bypassing treatment strategies in hemophilia and their effect on laboratory testing. Semin Thromb Hemost 2023; 49 (06) 651-660
• 37 George JN. Thrombotic thrombocytopenic purpura: from 1972 to 2022 and beyond. Semin Thromb Hemost 2022; 48 (08) 926-936
• 38 Larsen JB, Hvas AM, Hojbjerg JA. Platelet function testing: update and future directions. Semin Thromb Hemost 2023; 49 (06) 600-608
• 39 Kearney KJ, Spronk HMH, Emsley J, Key NS, Philippou H. Plasma Kallikrein as a Forgotten Clotting Factor. Semin Thromb Hemost 2024; , in press. DOI: 10.1055/s-0043-57034.
• 40 Li W, Hobson EC, Bunch CM. et al. Resonant acoustic rheometry to measure coagulation kinetics in hemophilia a and healthy plasma: a novel viscoelastic method. Semin Thromb Hemost 2023; 49 (02) 201-208
• 41 Shamanaev A, Litvak M, Ivanov I. et al. Factor XII structure-function relationships. Semin Thromb Hemost 2023; (e-pub ahead of print) DOI: 10.1055/s-0043-1769509.
• 42 Valerio L, Baddour LM. Septic pulmonary embolism: a contemporary profile. Semin Thromb Hemost 2023; 49 (08) 840-847
• 43 Richard M, Celeny D, Neerman-Arbez M. Mutations accounting for congenital fibrinogen disorders: an update. Semin Thromb Hemost 2022; 48 (08) 889-903
• 44 Hirsh J, de Vries TAC, Eikelboom JW, Bhagirath V, Chan NC. Clinical studies with anticoagulants that have changed clinical practice. Semin Thromb Hemost 2023; 49 (03) 242-254
• 45 Casini A, Moerloose P, Neerman-Arbez M. One hundred years of congenital fibrinogen disorders. Semin Thromb Hemost 2022; 48 (08) 880-888
• 46 Andersson NG, Kenet G. Intracranial hemorrhages in neonates: incidence, risk factors, and treatment. Semin Thromb Hemost 2023; 49 (04) 409-415
• 47 Ichinose A, Osaki T, Souri M, Favaloro EJ. A review of autoimmune acquired von Willebrand factor deficiency in Japan. Semin Thromb Hemost 2022; 48 (08) 911-925
• 48 Malinowski AK, Abdul-Kadir R. Planning pregnancy and birth in women with inherited bleeding disorders. Semin Thromb Hemost 2023; 49 (04) 371-381
• 49 Marlar RA. Laboratory evaluation of antithrombin, protein C, and protein S. Semin Thromb Hemost 2023; 49 (06) 641-650
• 50 Woods AI, Paiva J, Dos Santos C, Alberto MF, Sánchez-Luceros A. From the discovery of ADAMTS13 to current understanding of its role in health and disease. Semin Thromb Hemost 2023; 49 (03) 284-294
• 51 Iba T, Levi M, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Semin Thromb Hemost 2020; 46 (01) 89-95
• 52 Favaloro EJ. Celebrating 50 years of seminars in thrombosis and hemostasis-part I. Semin Thromb Hemost 2022; 48 (08) 871-874
• 53 Favaloro EJ. Celebrating 50 years of seminars in thrombosis and hemostasis-part II. Semin Thromb Hemost 2023; 49 (03) 212-216
• 54 Favaloro EJ. Celebrating 50 years of seminars in thrombosis and hemostasis-part III. Semin Thromb Hemost 2024; 50 (01) 4-7
• 55 Favaloro EJ, Pasalic L, Lippi G. Review and evolution of guidelines for diagnosis of COVID-19 vaccine induced thrombotic thrombocytopenia (VITT). Clin Chem Lab Med 2021; 60 (01) 7-17
• 56 Favaloro EJ, Pasalic L. Heparin-induced thrombotic thrombocytopenia (HITT) and vaccine-induced immune thrombotic thrombocytopenia (VITT): similar but different. Methods Mol Biol 2023; 2663: 405-415
• 57 Favaloro EJ, Pasalic L, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part IV. Semin Thromb Hemost 2023; 49 (01) 3-8
• 58 Smock KJ, Gosselin RC. Laboratory diagnostics for thrombosis and hemostasis testing-part II. Semin Thromb Hemost 2023; 49 (06) 569-570
• 59 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part III. Semin Thromb Hemost 2022; 48 (01) 3-7

Publication History

Article published online:
08 March 2024